- Eckert & Ziegler has signed a supply agreement to provide SK Biopharmaceuticals with GMP-compliant Actinium-225 for radiopharmaceutical R&D.
- The agreement supports SK Biopharmaceuticals’ development pipeline, including an Ac-225-labelled candidate targeting multiple cancer types.
Eckert & Ziegler has entered a supply agreement with SK Biopharmaceuticals to provide Actinium-225 (Ac-225) for the company’s radiopharmaceutical research and development activities. SK Biopharmaceuticals, based in South Korea, is expanding its oncology pipeline with programmes focused on central nervous system disorders and advanced radiotherapeutics.
The agreement supports the development of SKL35501, an Ac-225-labelled radiopharmaceutical candidate with potential applications in colorectal, breast, pancreatic, and head and neck cancers. By securing a reliable supply of the alpha-emitting isotope, SK Biopharmaceuticals aims to progress SKL35501 and additional candidates within its growing pipeline.
“We are happy to support SK Biopharmaceuticals with our supply of GMP compliant Ac-225 in their promising preclinical and clinical programs.”
Dr Harald Hasselmann, CEO of Eckert & Ziegler
Donghoon Lee, CEO of SK Biopharmaceuticals, said a stable supply of Ac-225 is critical to advancing radiopharmaceutical therapies and highlighted Eckert & Ziegler’s long-established track record in supplying high-quality radioisotopes to the pharmaceutical industry.
Eckert & Ziegler supplies Gallium-68, Lutetium-177, Yttrium-90 and Actinium-225 in GMP quality to pharmaceutical organisations and research centres worldwide. The company provides radioisotope production, global logistics and CDMO services to support radiopharmaceutical development and commercialisation.
